<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04485754</url>
  </required_header>
  <id_info>
    <org_study_id>TeleFU</org_study_id>
    <nct_id>NCT04485754</nct_id>
  </id_info>
  <brief_title>Telemedicine Follow-up for Post-ACS Patients</brief_title>
  <official_title>Telemedicine Follow-up for Post-Acute Coronary Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomsk National Research Medical Center of the Russian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tomsk National Research Medical Center of the Russian Academy of Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to compare the safety of using telemedicine and office visit follow-up in
      post-acute coronary syndrome patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rehabilitation after acute coronary syndrome includes visits to the cardiologist's office at
      1, 2, 6 and 12 months after discharge. Due to the Covid-19 pandemic, visiting a
      cardiologist's office maybe impossible. In such cases telemedicine follow-up visit would be
      reasonable choice. Taking into account the absence of studies in this area, providing
      investigation evaluating parameters of safety for both methodics is relevant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACCE</measure>
    <time_frame>1 year</time_frame>
    <description>Major adverse cardiac and cerebrovascular events: cardiac death, myocardial infarction, or stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High level of MT optimization</measure>
    <time_frame>1 year</time_frame>
    <description>High Level of Medical Therapy Optimization is defined as a participant meeting all of the following goals: LDL &lt; 1.4 mmol/L and on any statin, blood pressure &lt; 140/90 mm/Hg (&lt;135/85 mm/Hg for patients with diabetes mellitus), on aspirin or other antiplatelet or anticoagulant, and not smoking. High level of medical therapy optimization is missing if any of the individual goals are missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PB &lt; 140/90 mm/Hg (&lt;135/85 mm/Hg for Diabetes)</measure>
    <time_frame>1 year</time_frame>
    <description>Blood pressure &lt; 140 mm/Hg (&lt;135/85 mm/Hg for for patients with diabetes mellitus)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL &lt; 1.4 mmol/L</measure>
    <time_frame>1 year</time_frame>
    <description>Low density lipoprotein&lt; 1.4 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Not smoking</measure>
    <time_frame>1 year</time_frame>
    <description>Not smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in overweight</measure>
    <time_frame>1 year</time_frame>
    <description>Decrease in overweight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspirin or other antiplatelet or anticoagulant</measure>
    <time_frame>1 year</time_frame>
    <description>Adherence to aspirin or other antiplatelet or anticoagulant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to prescribed medication</measure>
    <time_frame>1 year</time_frame>
    <description>Adherence to prescribed at discharge medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>Hospitalization for cardiac reasons</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>ACS - Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Telemedicine FU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Office FU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telemedicine FU</intervention_name>
    <description>Participant will get telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.</description>
    <arm_group_label>Telemedicine FU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Office FU</intervention_name>
    <description>Participant will get office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.</description>
    <arm_group_label>Office FU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. Age â‰¥ 40 years

          3. PCI with coronary artery stenting for ACS

          4. Angiographic success PCI

        Exclusion Criteria:

          1. Patients with cancer

          2. Severe CHF (EF LV &lt;35% or functional class of heart failure III-IV NYHA)

          3. Severe valvular heart disease or Prosthetic heart valves.

          4. Severe forms of CKD (GFR&lt;30mL/min)

          5. Planned staged revascularization during the next 12 months

          6. Planned surgery within the next 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan S Bessonov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tyumen Cardiology Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivan S Bessonov, MD, PhD</last_name>
    <phone>+79068237755</phone>
    <email>ivanbessnv@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stanislav S Sapozhnikov, MD</last_name>
    <phone>+79091919191</phone>
    <email>stas_ss@bk.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science</name>
      <address>
        <city>Tyumen</city>
        <zip>625026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan S Bessonov</last_name>
      <phone>+79068237755</phone>
      <email>ivanbessnv@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Stanislav S Sapozhnikov</last_name>
      <phone>+79091919191</phone>
      <email>stas_ss@bk.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 21, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Telemedicine follow-up visit</keyword>
  <keyword>Post-ACS rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

